MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sales of
common stock and...
$80,000,000
Net cash provided by
(used in) financing...
$74,450,741
Canceled cashflow
$5,549,259
Net increase
(decrease) in cash, cash...
$60,939,805
Canceled cashflow
$13,510,936
Costs paid in
connection with private...
$5,393,311
Payment of deferred
offering costs
$155,948
Loss on issuance of
convertible preferred stock...
$321,499,041
Warrant issuance cost
$3,102,649
Stock-based compensation
expense
$1,327,372
Accrued expenses and
other current...
$317,446
Prepaid expenses and
other current assets
-$109,219
Depreciation and
amortization
$5,442
Net cash used in
operating activities
-$13,510,936
Canceled cashflow
$326,361,169
Changes in fair value of
the warrant...
-$45,389,916
Investment income
$948,122
Net (loss) income
-$293,423,177
Canceled cashflow
$46,338,038
Changes in fair value of
the warrant...
-$45,389,916
Accounts payable
-$1,059,012
Loss on issuance of
convertible preferred stock...
$321,499,041
Loss from operations
-$15,102,970
Warrant issuance cost
$3,102,649
Foreign exchange losses
-$56,555
Total expenses
$15,102,970
Back
Back
Cash Flow
source: myfinsight.com
Minerva Neurosciences, Inc. (NERV)
Minerva Neurosciences, Inc. (NERV)